Hepatic fibrosis with the use of methotrexate for juvenile rheumatoid arthritis.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 2388211.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Methotrexate (MTX) is currently under study for use in juvenile rheumatoid arthritis. One complication of MTX is hepatotoxicity. Although liver function tests may be abnormal with its use, in this setting they do not correlate well with the development of hepatic fibrosis. Periodic liver biopsy is required to monitor for the hepatotoxic changes secondary to MTX. We describe and discuss the case of a 17-year-old woman who developed evidence of hepatic fibrosis after 3 years of MTX therapy.
Medical subject headings
- Arthritis, Juvenile
- Liver Cirrhosis
- Methotrexate